Invivyd Q2 FY26 net loss widens to $44.4 million; revenue rises 21% to $14.3 million

Reuters2026/08/13 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Invivyd posted Q2 2026 net product revenue of USD 14.3 million, up 21% on higher patient demand.
Net loss widened to USD 44.4 million; loss per share was USD 0.14.
R&D expenses jumped to USD 29.4 million due to higher contract research costs for the DECLARATION and LIBERTY trials.
SG&A expenses climbed to USD 29.5 million on higher personnel, communications and commercial-related costs; cash ended at USD 160.1 million.
DECLARATION enrollment is complete with top-line data planned later in Q3 2026; LIBERTY is fully dosed with data expected late Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809811) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Invivyd Q2 FY26 net loss widens to $44.4 million; revenue rises 21% to $14.3 million

You may also like

Crypto prices